Basilea Ceftobiprole Saga Wages On; U.S. Development Ditched
This article was originally published in The Pink Sheet Daily
After seven years of trying to get ceftobiprole approved in the U.S., Basilea said it would not run further clinical trials without a partner. Plans for a launch in Europe remain on track.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
The broad-spectrum cephalosporin, the first in a potential portfolio of hospital products for severe infections from the Swiss company, is nearing the market in the U.K. and Scandinavia.
The pediatric market represents 70%-75% of the market for pneumococcal vaccines; Merck & Co.'s Vaxneuvance was already approved for infants earlier this year.